Literature DB >> 18547689

Intradermal pre-exposure rabies vaccine elicits long lasting immunity.

David Brown1, John J Featherstone, Anthony R Fooks, Sharmeen Gettner, Elizabeth Lloyd, Martin Schweiger.   

Abstract

A retrospective cohort study of current rabies antibody titres from adults who received pre-exposure immunisation administered intradermally between 1994 and 2005, examining the decay in titre over time relative to the interval since last dose, and the total dose received. Participants receiving at least 0.6 ml total dose intradermally of vaccine over at least two clinic visits and all with three clinic visits, were shown to have an adequate titre with measurable levels of antibody indicating sero-conversion above 0.5 IU/ml, irrespective of the time interval since the last dose. No clear relationship was found between time interval since immunisation and the level of antibody. Using a schedule that administers 0.6 ml of rabies vaccine over three clinic visits the boosting interval could be extended towards ten years; substantially cheaper than the standard licensed intramuscular dosing schedule.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18547689     DOI: 10.1016/j.vaccine.2008.04.081

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Rabies in travelers.

Authors:  Philippe Gautret; Philippe Parola
Journal:  Curr Infect Dis Rep       Date:  2014-03       Impact factor: 3.725

2.  Using intradermal rabies vaccine to boost immunity in people with low rabies antibody levels.

Authors:  David Brown; Anthony R Fooks; Martin Schweiger
Journal:  Adv Prev Med       Date:  2011-05-25

Review 3.  Pre-exposure rabies prophylaxis: a systematic review.

Authors:  Jocelyn A Kessels; Sergio Recuenco; Ana Maria Navarro-Vela; Raffy Deray; Marco Vigilato; Hildegund Ertl; David Durrheim; Helen Rees; Louis H Nel; Bernadette Abela-Ridder; Deborah Briggs
Journal:  Bull World Health Organ       Date:  2016-11-25       Impact factor: 9.408

Review 4.  New human rabies vaccines in the pipeline.

Authors:  Anthony R Fooks; Ashley C Banyard; Hildegund C J Ertl
Journal:  Vaccine       Date:  2018-08-25       Impact factor: 3.641

5.  Immunogenicity and feasibility of intradermal vaccination against rabies in Quebec.

Authors:  Y Bui; M Sow; E Cambron-Goulet; E Levac; F Milord
Journal:  Can Commun Dis Rep       Date:  2015-03-05

Review 6.  The Route of Administration of Rabies Vaccines: Comparing the Data.

Authors:  Deborah J Briggs; Susan M Moore
Journal:  Viruses       Date:  2021-06-27       Impact factor: 5.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.